

7 July 2015 EMA/HMPC/715094/2013 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on Carum carvi L., aetheroleum

Final

Discussion in Working Party on European Union monographs and list	November 2013
(MLWP)	May 2014
	July 2014
	September 2014
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	24 November 2014
Start of public consultation	
End of consultation (deadline for comments)	15 March 2015
Rediscussion in MLWP	May 2015
Adoption by HMPC	7 July 2015

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs;
	traditional use; Carum carvi L., aetheroleum; Carvi aetheroleum; Caraway oil

BG (bulgarski): Ким, масло	LT (lietuvių kalba): Kmynų eterinis aliejus
CS (čeština): kmínová silice	LV (latviešu valoda): Ķimenes ēteriskā eļļa
DA (dansk): Kommenolie	MT (Malti): Żejt tal-karwija
DE (Deutsch): Kümmelöl	NL (Nederlands): Karwijolie
EL (elliniká): αιθέριο έλαιο κάρου	PL (polski): Olejek eteryczny kminkowy
EN (English): Caraway oil	PT (português): Óleo essencial de alcarávia
	1

ES (español): Alcaravea, aceite esencial de RO (română): ulei volatil de chimen ET (eesti keel): Köömneõli SK (slovenčina): Silica rasce

FI (suomi): kuminaöljy SL (slovenščina): eterično olje navadne kumine

FR (français): Carvi (huile essentielle de) SV (svenska): Kumminolja

HR (hrvatski): Kimono eterično ulje IS (íslenska):

NO (norsk): Karveolje HU (magyar): Köményolaj

IT (italiano): Cumino essenza



European Union herbal monograph on Carum carvi L., aetheroleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition 1,2

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Carum carvi L., aetheroleum (Caraway oil)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparation
	Essential oil

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparation in liquid dosage forms for oral use.
	Herbal preparation in semi-solid dosage forms for cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product for the symptomatic relief of digestive disorders such as bloating and flatulence.

¹The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. ²The material complies with the Ph. Eur. monograph (ref.: 1817)

Well-established use	Traditional use
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Oral use
	Adults and elderly
	Daily dose: 0.15-0.3 ml of the essential oil divided in 1-3 doses daily.
	The oral use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Cutaneous use
	Infants, children, adolescents, adults and elderly
	Daily dose: 2 % semi-solid preparations to be applied once daily as a thin layer on the abdominal area.
	Duration of use
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.
	Cutaneous use.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance or to other plants of the Apiaceae (Umbelliferae) family (fennel, anise, celery, coriander and dill).

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Cutaneous use
	The product should not be used on broken skin, around the eyes or on mucous membranes.
	Oral use
	The oral use in children and adolescents under 18 years of age has not been established due to lack of adequate data.
	The use in patients with liver disease, cholangitis, achlorhydria, gallstones and any other biliary disorders is not recommended.
	Oral and Cutaneous use
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use	
	No studies on the effect on the ability to drive and use machines have been performed.	

4.8. Undesirable effects

Well-established use	Traditional use	
	None known.	
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.	

4.9. Overdose

Well-established use	Traditional use	
	No case of overdose has been reported.	

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use	
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.	

5.3. Preclinical safety data

Vell-established use Traditional use	
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7.	. Date of compilation/last revision					
7 Ju	7 July 2015					